Source-BBN Times
Oran Knowlson, a 13-year-old from Somerset, has made medical history as the first patient worldwide to undergo a revolutionary epilepsy treatment. Diagnosed with Lennox-Gastaut syndrome at the age of three, Oran has endured daily seizures, ranging from dozens to hundreds, severely impacting his quality of life. Traditional treatments had proven ineffective, prompting his participation in the CADET project—a cutting-edge trial at Great Ormond Street Hospital.
The centerpiece of this trial is the Picostim neurostimulator, developed by UK company Amber Therapeutics. Unlike previous models placed in the chest, this device is implanted directly into Oran’s skull. In October 2023, under the expertise of consultant pediatric neurosurgeon Martin Tisdall, two electrodes were precisely inserted into Oran’s brain, targeting the thalamus—a critical brain region involved in seizure activity. The neurostimulator, a mere 3.5cm square, was secured in place within Oran’s skull, offering a potentially safer and more effective approach to managing epilepsy.
Oran’s mother, Justine, shared with the BBC the transformative impact of the device on Oran’s life. His daytime seizures have decreased by an astounding 80%, marking a significant improvement in his overall well-being. Previously dominated by the unpredictability of seizures—including episodes where Oran would lose consciousness and require emergency intervention—the family now sees a brighter future ahead.
Advancing Treatment and Technology
The success of Oran’s surgery not only offers hope to his family but also paves the way for future advancements in epilepsy treatment. The Picostim neurostimulator operates by emitting a continuous electrical pulse, aiming to disrupt abnormal brain activity that triggers seizures. Its innovative design, situated within the skull, minimizes the risk of complications such as infections—a common concern with previous chest-implanted devices. This approach not only enhances safety but also improves the device’s efficacy in managing Oran’s condition.
Martin Tisdall highlighted the significance of this trial in evaluating the effectiveness of deep brain stimulation for severe epilepsy. By placing the neurostimulator closer to the source of seizures, the medical team aims to optimize treatment outcomes while reducing potential risks associated with traditional implantation methods. Oran’s ability to recharge the device wirelessly, coupled with its discreet integration into his daily activities, underscores the device’s practicality and patient-centered design.
Looking Ahead to Future Hope
Looking ahead, Oran’s journey represents a beacon of hope for others grappling with treatment-resistant epilepsy. As part of the ongoing CADET project, three more children with Lennox-Gastaut syndrome are slated to receive the same neurostimulator treatment, further validating its potential impact on epilepsy treatment. For Justine and Oran’s family, the prospect of real-time responsive neurostimulation—a future phase of the trial—offers renewed optimism. This advancement could preempt seizures by actively monitoring and adjusting to Oran’s brain activity, potentially offering even greater control and freedom from the debilitating effects of epilepsy.
While acknowledging that the neurostimulator isn’t a cure, Oran’s family remains optimistic about his continued progress and integration into activities he enjoys, such as riding lessons. The journey ahead may not be without challenges, but with each milestone, Oran and his family are reclaiming hope and resilience in the face of epilepsy’s shadows. As medical technology evolves and trials like CADET progress, the future holds promise for enhancing the lives of individuals like Oran Knowlson, offering new pathways to manage and eventually conquer severe epilepsy.
Also Read: 5 Medicines That Can Be Used to Cure Multiple Diseases
